Institutional Investors May Adopt Severe Steps After CRISPR Therapeutics AG's (NASDAQ:CRSP) Latest 8.3% Drop Adds to a Year Losses
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
JMP Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $86
CRISPR Therapeutics: Promising Developments and Positive Outlook Amid Advancements in Gene-Editing
1 Big New Green Flag for CRISPR Therapeutics' Stock
Clear Street Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $45